Business / Finance

RSS

Leica Biosystems completes acquisition of Devicor Medical Products

Leica Biosystems, a global leader in anatomic pathology laboratory solutions and instruments, announced today that it has successfully completed its previously announced acquisition of Devicor Medical Products, Inc.

4 Dec 2014

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, today announces that it has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties.

4 Dec 2014

Swisslog Healthcare Solutions announces partnership with Visante healthcare consulting

Swisslog Healthcare Solutions, a leading supplier of automation solutions for materials transport and medication management, announces its partnership with Visante healthcare consulting at the American Society of Health-System Pharmacists Midyear Clinical Meeting in Anaheim, California - December 7 – 11, 2014.

3 Dec 2014

O2 Media acquires health and fitness e-retailer InboxFitness.com

O2 Media is pleased to announce that the company has acquired the health and fitness e-retailer InboxFitness.com.

3 Dec 2014

Garmatex, Diagnomics partner to develop healthcare products to prevent hospital-acquired infections

Garmatex Technologies, Inc., a leading inventor of performance fabric and apparel solution-focused technologies, has signed a Letter of Intent ("LOI") for a five year term with Diagnomics Inc., a biotech company that provides next-generation healthcare solutions from personal genomics.

3 Dec 2014

WLT agrees to make MediClaims software available to Advanzeon

Advanzeon Solutions, Inc., which provides behavioral health, substance abuse and pharmacy management services, as well as sleep apnea programs, to employers, Taft-Hartley health and welfare funds, and managed care companies throughout the U.S. is pleased to announce that it has entered into an Agreement with WLT Software Enterprises, Inc.

3 Dec 2014

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

IRIDEX Corporation (Nasdaq: IRIX) announced today that its China distributor has been awarded a competitive tender for more than $620,000 in ophthalmology laser equipment to fulfill a government program designed to provide advanced ophthalmology solutions to patients across vast areas of China's rural regions.

2 Dec 2014

AYOXXA Biosystems closes third round of Series B financing

AYOXXA Biosystems GmbH, an international biotechnology company, announces the closing of a third round of Series B financing, bringing the total amount raised to 11.3 Mio. EUR in 2014.

2 Dec 2014

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock.

2 Dec 2014

Otsuka Pharmaceutical to acquire Avanir Pharmaceuticals for $3.5B

Avanir Pharmaceuticals, Inc. today announced that it has entered into a definitive agreement with Otsuka Pharmaceutical Co., Ltd. pursuant to which Otsuka will acquire Avanir for $17.00 per share in cash.

2 Dec 2014

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs.

1 Dec 2014

Arthurian Life Sciences partners with Interrad Medical

Arthurian Life Sciences, the specialist fund management company led by Professor Sir Chris Evans, announced today it has formed a partnership with leading US medtech firm, Interrad Medical Inc.

1 Dec 2014

Plaza Centers' shareholders approve proposed rights offering

Elbit Imaging Ltd. ("Elbit" or the "Company") announced today, following its announcements dated June 23, 2014 and October 14, 2014, that its 62.25% owned subsidiary, Plaza Centers N.V. ("Plaza"), announced that Plaza's shareholders have approved the proposed rights offering (the "Rights Offering") which forms part of Plaza's restructuring plan.

29 Nov 2014

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

Valeant to redeem US$445.0M aggregate principal amount of 6.875% Senior Notes due 2018

Valeant Pharmaceuticals International, Inc. today announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem US$445.0 million aggregate principal amount of its outstanding 6.875% Senior Notes due 2018, CUSIP Nos. 91911XAN4, U9098VAF9 (the "Notes") on December 29, 2014 and has mailed an irrevocable notice of redemption for the Notes.

29 Nov 2014

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its accomplishments and financial results for the three months ended September 30, 2014.

29 Nov 2014

Roche Holdings declares final results of its previously announced tender offer

Roche Holdings, Inc. (the "Offeror") announced today the final results of its previously announced tender offer (the "Offer") to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2.2 billion (the "Maximum Tender Amount") the 5.25% Senior Notes due 2035 issued by the Offeror's subsidiary Genentech, Inc.

29 Nov 2014

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.

27 Nov 2014

CARsgen announces completion of series A financing

CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund.

26 Nov 2014

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, today announces the completion of its Series C fundraising round. The company has raised €25.33 million ($31.4 million), including €20.33 million in capital.

26 Nov 2014

Business / Finance

Leica Biosystems completes acquisition of Devicor Medical Products

Alizé Pharma obtains exclusive worldwide rights to develop new therapy for bone diseases

Swisslog Healthcare Solutions announces partnership with Visante healthcare consulting

O2 Media acquires health and fitness e-retailer InboxFitness.com

Garmatex, Diagnomics partner to develop healthcare products to prevent hospital-acquired infections

WLT agrees to make MediClaims software available to Advanzeon

IRIDEX's China distributor secures large tender to supply ophthalmology laser equipment

AYOXXA Biosystems closes third round of Series B financing

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Otsuka Pharmaceutical to acquire Avanir Pharmaceuticals for $3.5B

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Arthurian Life Sciences partners with Interrad Medical

Plaza Centers' shareholders approve proposed rights offering

iCo Therapeutics announces corporate update and Q3 2014 financial results

Valeant to redeem US$445.0M aggregate principal amount of 6.875% Senior Notes due 2018

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Roche Holdings declares final results of its previously announced tender offer

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

CARsgen announces completion of series A financing

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News